{
    "clinical_study": {
        "@rank": "134351", 
        "arm_group": [
            {
                "arm_group_label": "IGIV, 10% at 0.2 g/kg body weight", 
                "arm_group_type": "Experimental", 
                "description": "IGIV, 10% at 0.2 g/kg body weight every 2 weeks for up to 3 years, 6 months."
            }, 
            {
                "arm_group_label": "IGIV, 10% at 0.4 g/kg body weight", 
                "arm_group_type": "Experimental", 
                "description": "IGIV, 10% at 0.4 g/kg body weight every 2 weeks for up to 3 years, 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this long-term study is to provide additional evidence of safety and efficacy\n      of IGIV, 10% treatment in participants with Alzheimer\u00b4s Disease who have completed the Phase\n      3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg\n      or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701.\n      Participants and investigators will be blinded to dose unless otherwise notified by the\n      sponsor."
        }, 
        "brief_title": "Long-Term Study of IGIV, 10% in Alzheimer\u00b4s Disease", 
        "condition": "Alzheimer\u00b4s Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          -  Completed 18 months of study treatment and assessments in Baxter precursor study\n             160701\n\n          -  Diagnosis of probable Alzheimer\u00b4s Disease (AD)\n\n          -  Able to comply with testing and infusion regimen (including adequate corrected visual\n             acuity and hearing ability)\n\n          -  Has a caregiver (study partner) who is willing and able to participate\n\n        Main Exclusion Criteria:\n\n          -  Significant neurological disease other than AD\n\n          -  Clinically significant cardiac/cardiovascular problems (e.g. uncontrolled blood\n             pressure, atrial fibrillation, heart disease, clotting disorders, strokes, or recent\n             heart attack)\n\n          -  Contraindication to undergoing MRI (e.g. pacemaker [with the exception of an\n             MRI-compatible pacemaker], severe claustrophobia, ferromagnetic implants such as a\n             metal plate)\n\n          -  Specific findings on brain MRI (microhemorrhages, superficial siderosis, vasogenic\n             edema, a macrohemorrhage, major stroke, or multiple lacunae)\n\n          -  Active malignancy or history of malignancy within 5 years prior to screening with the\n             exception of the following: adequately treated basal cell or squamous cell carcinoma\n             of the skin, carcinoma in situ of the cervix, and stable prostate cancer not\n             requiring treatment\n\n          -  Uncontrolled major depression, psychosis, or other major psychiatric disorder(s)\n\n          -  Poorly controlled diabetes\n\n          -  Serious problems with liver or kidneys\n\n          -  Known history of hypersensitivity following infusions of human blood or blood\n             components (e.g. human immunoglobulins or human albumin)\n\n          -  Current or recent treatment with immunomodulatory therapies (with the exception of\n             immunoglobulin and non-systemic and low-dose systemic corticosteroids)\n\n          -  Recent use of investigational drugs or biologics, including those aimed at altering\n             AD progression (with the exception of immunoglobulin)\n\n          -  Active immunization for the treatment of AD at any time\n\n        There are reasons why it might not be appropriate to participate in this trial. Please\n        contact Medical Information at medinfo@baxter.com for details."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "51 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736579", 
            "org_study_id": "161202"
        }, 
        "intervention": {
            "arm_group_label": [
                "IGIV, 10% at 0.2 g/kg body weight", 
                "IGIV, 10% at 0.4 g/kg body weight"
            ], 
            "intervention_name": "Immune Globulin Intravenous (Human), 10% (IGIV, 10%)", 
            "intervention_type": "Drug", 
            "other_name": "Gammagard Liquid"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Immunoglobulins, Intravenous", 
                "Rho(D) Immune Globulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study of the Long-Term Safety and Efficacy of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) in Mild to Moderate Alzheimer\u00b4s Disease", 
        "overall_official": {
            "affiliation": "Baxter Healthcare Corporation", 
            "last_name": "Kathy Tobias, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence and severity of treatment-emergent adverse events (AEs) and serious adverse events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years, 6 months"
            }, 
            {
                "measure": "Number of infusions discontinued, slowed, or interrupted due to an AE/SAE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years, 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736579"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Cognition and activities of daily living", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 years, 6 months"
        }, 
        "source": "Baxter Healthcare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baxter Healthcare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013", 
        "why_stopped": "The study was terminated because the first Phase 3 did not demonstrate efficacy on the\n    co-primary endpoints. The known safety profile remained unchanged."
    }
}